ProCE Banner Activity

LA ART for HIV Treatment and Prevention: CROI 2024 Update

Conference Coverage
Clinical Thought

LA ART for HIV treatment and prevention is increasingly available as a switch strategy for virologically suppressed individuals in high-income countries, but access is limited for people with adherence challenges and for those in low- and middle-income countries. Learn how several key studies presented at CROI 2024 expand the populations for which data on the use of LA ART are available, inform future LA options, and underline the importance of LA PrEP as an option for expanding PrEP coverage. 

Released: April 02, 2024

Expiration: April 01, 2025

Share

Faculty

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant financial relationships to disclose.